1 to 5 of 5 literature results

• CXCR4 acts as a costimulator during thymic beta-selection.

  Passage through the beta-selection developmental checkpoint requires productive rearrangement of segments of the T cell antigen receptor-beta gene (Tc…

  Authors: Paul C Trampont, Annie-Carole Tosello-Trampont, Yuelei Shen, Amanda K Duley, Ann E Sutherland, Timothy P Bender, Dan R Littman, Kodi S Ravichandran

  Source: Nature immunology. 2010 Feb

  View Full Text

• How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets.

  CD4(+)Foxp3(+) regulatory T cells (Treg cells) are known to control the progression of autoimmune diabetes, but when, where, and how they exert their …

  Authors: Markus Feuerer, Yuelei Shen, Dan R Littman, Christophe Benoist, Diane Mathis

  Source: Immunity. 2009 Oct 16

  View Full Text

• TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function.

  T helper cells that produce IL-17 (T(H)17 cells) promote autoimmunity in mice and have been implicated in the pathogenesis of human inflammatory disea…

  Authors: Liang Zhou, Jared E Lopes, Mark M W Chong, Ivaylo I Ivanov, Roy Min, Gabriel D Victora, Yuelei Shen, Jianguang Du, Yuri P Rubtsov, Alexander Y Rudensky,…

  Source: Nature. 2008 May 8

  View Free Full Text

• The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation.

  Most antigenic peptides presented on MHC class I molecules are generated by proteasomes during protein breakdown. It is unknown whether these peptides…

  Authors: Ian A York, Annie X Y Mo, Kristen Lemerise, Wanyong Zeng, Yuelei Shen, Carmela R Abraham, Tomo Saric, Alfred L Goldberg, Kenneth L Rock

  Source: Immunity. 2003 Mar

  View Full Text

• Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.

  Interference with inhibitory immunological checkpoints controlling T cell activation provides new opportunities to augment cancer immunotherapies. Whe…

  Authors: Sergio A Quezada, Karl S Peggs, Tyler R Simpson, Yuelei Shen, Dan R Littman, James P Allison

  Source: The Journal of experimental medicine. 2008 Sep 1

  View Full Text